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The most  common cause of pulmonary infection 
exacerbations in patients with cystic fibrosis is Pseudomonas 
aeruginosa,  which accounts for 37.5 % (1).  
 
The treatment of choice for such infection is combination 
therapy of aminoglycosides, usually tobramycin, and a b-
lactam, e.g. ceftazidime.  
 
Aminoglycosides are narrow therapeutic index drugs and 
hence require routine therapeutic drug monitoring to ensure 
efficacy and safety. 
  
There is a wide range of variability in aminoglycoside 
pharmacokinetics, and dosage individualisation is required.  
AIMS 
To compare the results of parametric and nonparametric 
analyses of the population PK of aminoglycosides in patients 
with  cystic fibrosis.  
METHODS 
Aminoglycoside dosage histories and concentration 
measurements were available from patients with cystic fibrosis 
from Glasgow and The Hague.  
 
The data were analysed using parametric population modelling 
approach with NONMEM (version 7, FOCE) (2) and a non-
parametric approach with the software Pmetrics  (version 0.3, 
NPAG) (3). 
 
The parameter estimates, structural models and covariate 
models using both simple and mechanistic approaches, were 
compared between the parametric and non-parametric 
approaches. 
RESULTS 
Table 1:  Summary of patient characteristics 
CONCLUSION 
Similar results were obtained when parametric and nonparametric 
approaches were used to analyse aminoglycoside data from 
patients with cystic fibrosis. 
Key: CrCL= Estimated creatinine clearance by Cockcroft and Gault equation (4) with serum 
creatinine concentration fixed to 60 µmol/L if less than 60 µmol/L 
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BACKGROUND 
Patient 
Characteristic 
Glasgow data 
n = 166 
The Hague data 
  n = 165 
Median Range Median Range 
Age (years) 23 14 - 66 32 14  – 88 
Weight (kg) 50 30 - 86 60 35 – 108 
Height (cm) 163 139 - 191 174 150 – 194 
CLcr (ml/min) 92 35 - 181 104 26 – 174 
Parameter 
Pmetrics 
Mean (CV %) 
NONMEM 
Typical value (CV %) 
CL (L/h) 5.24 (23 %) 4.85 (25 %) 
V (L) 14.8 (21 %) 14.1 (15 %) 
Q (L/h) 0.434 (21 %) 0.596 (79 %) 
Vp (L) 7.08 (13.8 %) 7.18 (59 %) 
A two compartment model was superior to one compartment 
model with both approaches. 
 
Table 2:  Parameter estimates of the two compartment base model 
using NONMEM and Pmetrics 
Pmetrics 
NONMEM  
Figure 1:  Measured versus predicted aminoglycoside 
concentrations using the final model.  
 
   
  
  
  
 
The dashed line is a smooth line  
Parameter Pmetrics NONMEM  
CL (L/h) 
0.03(L/h/cm) * HT(cm) + 0.02(L/h)* 
(CrCL(mL/min) - 94) 
0.03(L/h/cm) * HT(cm) + 0.01(L/h)* 
(CrCL(mL/min) - 94) 
V (L) 14.2 (L)*(1 + 0.013 *(HT - 166)) 13.9 (L)*(1 + 0.011* (HT - 166)) 
Q (L/h) 0.6 0.6 
Vp (L) 8.00 5.79 
Table 4:  Parameter estimates of final population models 
Key: HT= Height, CrCL= Estimated creatinine clearance by Cockcroft and Gault equation (4) with serum 
creatinine concentration fixed to 60 µmol/L if less than 60 µmol/L 
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Model 
Pmetrics NONMEM 
Likelihood OFV 
CL= CL 
V= V 
9004  2866 
CL=CL0 x LBW + CLs (CrCL- 94) 
V=V0(1+Vs(LBW-40)) 
9061 2916 
CL=CL0 x Weight + CLs (CrCL- 94) 
V=V0 x (1 + Vs (Weight - 53)) 
8989 3037 
CL=CL0(LBW/70)
0.75 +CLs X RF       
V=V0X(1+Vs(LBW+(WT-LBW)/70))  
8789 3048 
CL=CL0 x BSA + CLs (CrCL- 94) 
V=V0 (1+Vs (BSA - 1.6)) 
8675 2977 
CL=CL0 x Height + CLs (CrCL- 94) 
V=V0 x (1 + Vs (Height - 166)) 
8568 2848 
Key: CrCL= Estimated creatinine clearance by Cockcroft and Gault equation (4) with serum creatinine concentration 
fixed to 60 µmol/L if less than 60 µmol/L, LBW= Lean body weight (5), BSA= Body surface area (6), Renal function 
estimated by Anderson and Holford approach (7) 
Table 3:  Covariate development process  
